Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.
Alexion discovered and developed Soliris? (eculizumab), a first-in-class terminal complement inhibitor. Today, Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States and European Union as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Soliris is not indicated for the treatment of patients with Shiga toxin E coli-related hemolytic uremic syndrome (STEC-HUS). Alexion is working urgently to investigate Soliris and additional product candidates as treatments for patients with other rare and severe diseases.
?
United Kingdom
